US 11,717,484 B2
Topical treatment of inflammatory bowel disease using antibodies and fragments thereof
Vipul Yadav, London (GB); Abdul Waseh Basit, Middlesex (GB); Felipe José Oliveira Varum, Rheinfelden (CH); Roberto Carlos Bravo Gonzaléz, Rheinfelden (CH); and Esther Maria Furrer, Rheinfelden (CH)
Assigned to Tillotts Pharma AG, Rheinfelden (CH); and University College London, England (GB)
Appl. No. 16/616,460
Filed by Tillotts Pharma AG, Rheinfelden (CH); and University College London, London (GB)
PCT Filed Apr. 26, 2018, PCT No. PCT/EP2018/060690
§ 371(c)(1), (2) Date Nov. 23, 2019,
PCT Pub. No. WO2018/219559, PCT Pub. Date Dec. 6, 2018.
Claims priority of application No. 17173847 (EP), filed on May 31, 2017.
Prior Publication US 2020/0170956 A1, Jun. 4, 2020
Int. Cl. A61K 9/28 (2006.01); A61K 9/00 (2006.01); C07K 16/24 (2006.01)
CPC A61K 9/288 (2013.01) [A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); C07K 16/241 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01)] 13 Claims
 
1. A composition comprising (i) an active agent selected from the group consisting of antibodies specific to tumor necrosis factor alpha (TNFα) and functional fragments thereof and (ii) an amount of one or more suitable buffer agents and/or acidifiers effective to reduce the luminal pH in the large intestine, wherein said composition is formulated for rectal administration for use in the treatment of an inflammatory bowel disease in a human patient, further wherein administration of said composition results in the local accumulation of said active agent in the gastrointestinal wall and a decrease of a pH in the large intestinal lumen of said patient to between 5.5 and 6.5.